Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $2.5 million.

  • Tango Therapeutics' Depreciation & Amortization (CF) fell 7.50% to $555,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 4.49%. This contributed to the annual value of $2.5 million for FY2024, which is 3.52% up from last year.
  • Tango Therapeutics' Depreciation & Amortization (CF) amounted to $2.5 million in FY2024, which was up 3.52% from $2.4 million recorded in FY2023.
  • Tango Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.5 million for FY2024, and its period low was $718,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $2.2 million, with a median of $2.4 million in 2023.
  • Data for Tango Therapeutics' Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 78.67% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Tango Therapeutics' Depreciation & Amortization (CF) stood at $718,000 in 2020, then grew by 25.35% to $900,000 in 2021, then spiked by 78.67% to $1.6 million in 2022, then spiked by 50.19% to $2.4 million in 2023, then increased by 3.52% to $2.5 million in 2024.